Foxborough, MA, United States of America

Giordano Caponigro

USPTO Granted Patents = 13 (Patent Applications = 23)

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 28)

Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 51(Granted Patents)

Location History:

Cambridge, MA (US) (2018 - 2022)
Foxborough, MA (US) (2016 - 2024)

Company Filing History:

Years Active: 2016-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12011449 - Therapeutic combinations comprising a c-RAF inhibitor (2024-06-18),

2. 11406627 - Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers (2022-08-09),

3. 11376239 - Pharmaceutical combinations (2022-07-05),

4. 10973829 - Therapeutic uses of a C-RAF inhibitor (2021-04-13),

5. 10548894 - Combination therapy (2020-02-04),

6. 10485788 - Pharmaceutical combinations (2019-11-26),

7. 10328066 - Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer (2019-06-25),

8. 10328065 - Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer (2019-06-25),

9. 10011874 - Androgen receptor mutation (2018-07-03),

10. 9913844 - Combination therapy (2018-03-13),

11. 9867825 - Pharmaceutical combination comprising binimetinib (2018-01-16),

12. 9700557 - Pharmaceutical combinations of a CDK4/6 inhibitor and a B-RAF inhibitor (2017-07-11),

13. 9474754 - Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor (2016-10-25),

Title: Giordano Caponigro: Innovator in Cancer Treatment

Introduction

Giordano Caponigro is a prominent inventor based in Foxborough, MA (US), known for his significant contributions to the field of cancer treatment. With a total of 13 patents, he has developed innovative therapeutic combinations that aim to improve patient outcomes in oncology.

Latest Patents

Caponigro's latest patents include groundbreaking inventions such as "Therapeutic combinations comprising a c-RAF inhibitor." This invention focuses on a combination treatment that includes at least one ERK inhibitor and a c-RAF inhibitor, which can be administered simultaneously, separately, or sequentially. The aim is to treat proliferative diseases, particularly advanced solid tumors with MAPK alterations. Another notable patent is "Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers." This invention outlines a pharmaceutical combination of an MDM2 inhibitor and an ERK inhibitor, designed for effective cancer treatment.

Career Highlights

Throughout his career, Giordano Caponigro has worked with leading pharmaceutical companies, including Novartis AG and Array Biopharma Inc. His work has significantly impacted the development of cancer therapies, showcasing his dedication to advancing medical science.

Collaborations

Caponigro has collaborated with notable professionals in the field, including Darrin Stuart and Scott Delach. These partnerships have contributed to the success of his innovative projects and patents.

Conclusion

Giordano Caponigro's work exemplifies the spirit of innovation in cancer treatment. His patents and collaborations reflect a commitment to improving therapeutic options for patients facing challenging diagnoses.

This text is generated by artificial intelligence and may not be accurate.